183 related articles for article (PubMed ID: 28785080)
1. Clinical dosage of meclozine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia.
Matsushita M; Esaki R; Mishima K; Ishiguro N; Ohno K; Kitoh H
Sci Rep; 2017 Aug; 7(1):7371. PubMed ID: 28785080
[TBL] [Abstract][Full Text] [Related]
2. Meclozine promotes longitudinal skeletal growth in transgenic mice with achondroplasia carrying a gain-of-function mutation in the FGFR3 gene.
Matsushita M; Hasegawa S; Kitoh H; Mori K; Ohkawara B; Yasoda A; Masuda A; Ishiguro N; Ohno K
Endocrinology; 2015 Feb; 156(2):548-54. PubMed ID: 25456072
[TBL] [Abstract][Full Text] [Related]
3. Maternal administration of meclozine for the treatment of foramen magnum stenosis in transgenic mice with achondroplasia.
Matsushita M; Mishima K; Esaki R; Ishiguro N; Ohno K; Kitoh H
J Neurosurg Pediatr; 2017 Jan; 19(1):91-95. PubMed ID: 27767902
[TBL] [Abstract][Full Text] [Related]
4. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
5. Long-term oral meclozine administration improves survival rate and spinal canal stenosis during postnatal growth in a mouse model of achondroplasia in both sexes.
Funahashi H; Matsushita M; Esaki R; Mishima K; Ohkawara B; Kamiya Y; Takegami Y; Ohno K; Kitoh H; Imagama S
JBMR Plus; 2024 Apr; 8(4):ziae018. PubMed ID: 38544920
[TBL] [Abstract][Full Text] [Related]
6. Intermittent PTH (1-34) injection rescues the retarded skeletal development and postnatal lethality of mice mimicking human achondroplasia and thanatophoric dysplasia.
Xie Y; Su N; Jin M; Qi H; Yang J; Li C; Du X; Luo F; Chen B; Shen Y; Huang H; Xian CJ; Deng C; Chen L
Hum Mol Genet; 2012 Sep; 21(18):3941-55. PubMed ID: 22634226
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety after once and twice a day doses of meclizine hydrochloride administered to children with achondroplasia.
Kitoh H; Matsushita M; Mishima K; Nagata T; Kamiya Y; Ueda K; Kuwatsuka Y; Morikawa H; Nakai Y; Ishiguro N
PLoS One; 2020; 15(4):e0229639. PubMed ID: 32282831
[TBL] [Abstract][Full Text] [Related]
8. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
[TBL] [Abstract][Full Text] [Related]
9. HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia.
Ota S; Zhou ZQ; Romero MP; Yang G; Hurlin PJ
Hum Mol Genet; 2016 Oct; 25(19):4227-4243. PubMed ID: 27506979
[TBL] [Abstract][Full Text] [Related]
10. Activated FGFR3 prevents subchondral bone sclerosis during the development of osteoarthritis in transgenic mice with achondroplasia.
Okura T; Matsushita M; Mishima K; Esaki R; Seki T; Ishiguro N; Kitoh H
J Orthop Res; 2018 Jan; 36(1):300-308. PubMed ID: 28520086
[TBL] [Abstract][Full Text] [Related]
11. Constitutively-active FGFR3 disrupts primary cilium length and IFT20 trafficking in various chondrocyte models of achondroplasia.
Martin L; Kaci N; Estibals V; Goudin N; Garfa-Traore M; Benoist-Lasselin C; Dambroise E; Legeai-Mallet L
Hum Mol Genet; 2018 Jan; 27(1):1-13. PubMed ID: 29040558
[TBL] [Abstract][Full Text] [Related]
12. Activated FGFR3 promotes bone formation via accelerating endochondral ossification in mouse model of distraction osteogenesis.
Osawa Y; Matsushita M; Hasegawa S; Esaki R; Fujio M; Ohkawara B; Ishiguro N; Ohno K; Kitoh H
Bone; 2017 Dec; 105():42-49. PubMed ID: 28802681
[TBL] [Abstract][Full Text] [Related]
13. Phase 1b study on the repurposing of meclizine hydrochloride for children with achondroplasia.
Matsushita M; Kitoh H; Mishima K; Kamiya Y; Kato D; Takemoto G; Sawamura K; Ueno S; Yasuhiro N; Nishida K; Imagama S
PLoS One; 2023; 18(7):e0283425. PubMed ID: 37428729
[TBL] [Abstract][Full Text] [Related]
14. Knock-in human FGFR3 achondroplasia mutation as a mouse model for human skeletal dysplasia.
Lee YC; Song IW; Pai YJ; Chen SD; Chen YT
Sci Rep; 2017 Feb; 7():43220. PubMed ID: 28230213
[TBL] [Abstract][Full Text] [Related]
15. PTH has the potential to rescue disturbed bone growth in achondroplasia.
Ueda K; Yamanaka Y; Harada D; Yamagami E; Tanaka H; Seino Y
Bone; 2007 Jul; 41(1):13-8. PubMed ID: 17466614
[TBL] [Abstract][Full Text] [Related]
16. C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.
Legeai-Mallet L
Endocr Dev; 2016; 30():98-105. PubMed ID: 26684019
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
[TBL] [Abstract][Full Text] [Related]
18. Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
Yamashita A; Morioka M; Kishi H; Kimura T; Yahara Y; Okada M; Fujita K; Sawai H; Ikegawa S; Tsumaki N
Nature; 2014 Sep; 513(7519):507-11. PubMed ID: 25231866
[TBL] [Abstract][Full Text] [Related]
19. Achondroplasia: from genotype to phenotype.
Richette P; Bardin T; Stheneur C
Joint Bone Spine; 2008 Mar; 75(2):125-30. PubMed ID: 17950653
[TBL] [Abstract][Full Text] [Related]
20. Achondroplasia: Development, pathogenesis, and therapy.
Ornitz DM; Legeai-Mallet L
Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
